Talk:Belimumab

Target
I think it is B lymphocyte stimulator, not really anti-TNF. Regards, Blake3522 09:47, 13 July 2007 (UTC)

Side effects etc
It would be greatly appreciated to know data that we are told about other medications, such as side affects, method of ingestion (pill, injection, IV, etc.) and any other info that is usually included in a drug description for the layman. —Preceding unsigned comment added by Penlady (talk • contribs) 21:54, 21 June 2009 (UTC)


 * I second the idea of adding in information regarding side effects and clinical trials so as to better educate visitors about this drug. It's vital given that it's been a long while before any major drug has been released that specifically targeted lupus. Kinsho 06:32, 25 December 2009 (UTC)

Clinical trial endpoint
It should be noted that the clinical trial endpoint was rigourous: 'At Wk52, the percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score and no worsening in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.' Patients can experience clinical benefit while not making all these criteria;  this is one of the basic differences between clinical research and ordinary medicine. Cranham  13 Mar 2011
 * Yes, they can benefit even if the results are negative, but then, they might not benefit. We can't tell, and saying "people might benefit, or maybe not" isn't really valuable information. --ἀνυπόδητος (talk) 10:48, 14 March 2011 (UTC)

30 October 2000
Under history, there is a sentence that just says On 30 October 2000 "Human Genome Sciences and Cambridge Antibody Technology Commit to Exclusive Development of Anti-BLyS Antibodies". Is this supposed to be a reference to the sentence before and they should therefore be combined? Cleanelephant (talk) 20:16, 6 December 2011 (UTC)

NEJM
Good recent review article:

--Nbauman (talk) 04:38, 19 April 2013 (UTC)


 * Free access NEJM blog summary:
 * http://blogs.nejm.org/now/index.php/belimumab-for-sle/2013/04/19/
 * NOW@NEJM
 * Belimumab for SLE
 * Posted by Sara Fazio • April 19th, 2013
 * In the latest review article in our Clinical Therapeutics series, a 20-year-old woman with SLE presents with disease flares and receives belimumab, a monoclonal antibody that binds to B-cell activating factor, inhibiting B-cell stimulation. Belimumab is considered for patients who do not have a response or have adverse effects with first-line therapies.
 * --Nbauman (talk) 19:05, 20 April 2013 (UTC)

False copyvio positive
http://www.usmlextract.com/2013/06/belitumab.html is apparently a false positive for copyright violations on this article. It is an uncredited copy that includes at least one phrase that was added to this article in November of 2012, as well as mangled versions of characters created in the article with wiki markup. — Preceding unsigned comment added by 198.45.215.17 (talk) 16:42, 11 November 2013 (UTC)
 * Yes, that looks very much like USMLE is the copyright violator. --ἀνυπόδητος (talk) 11:50, 12 November 2013 (UTC)

External links modified
Hello fellow Wikipedians,

I have just added archive links to 1 one external link on Belimumab. Please take a moment to review my edit. If necessary, add after the link to keep me from modifying it. Alternatively, you can add to keep me off the page altogether. I made the following changes:
 * Added archive https://web.archive.org/20110317151651/http://www.gsk.com:80/media/pressreleases/2011/2011_us_pressrelease_10017.htm to http://www.gsk.com/media/pressreleases/2011/2011_us_pressrelease_10017.htm

When you have finished reviewing my changes, please set the checked parameter below to true to let others know.

Cheers.—cyberbot II  Talk to my owner :Online 11:32, 22 February 2016 (UTC)